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Monocytes and Polymorphonuclear Neutrophils of Patients with Streptococcal
Pharyngitis Express Increased Numbers of Type I IgG Fc Receptors
Paul M. Guyre,* A. Scott Campbell,tl Wayne D. Kniffin,' and Michael W. Fangert
Departments of*Physiology, tMicrobiology, and §Medicine, Dartmouth Medical School, Hanover, New Hampshire 03756

Abstract
Studies using cultured cells have shown that gamma interferon
(IFN-'y) induces the expression of FcyRI (the type I Fc receptor for IgG) on human polymorphonuclear neutrophils (PMN)
and greatly increases the number of these receptors on human
monocytes. Administration of rIFN-y in vivo also causes enhanced Fc'yRI expression od these cell populations. Because
streptococcal antigens are potent inducers of IFN-y in vitro, we
postulated that IFN-'y would be produced endogenously in vivo
in patients with streptococcal infections. Such production of
IFN--y in vivo, even at low levels, might be expected to induce
the expression of FcyRI on monocytes and neutrophils. To
evaluate this possibility, we used monoclonal antibody 32
(mAb 32), which is specific for FcyRI, to quantitate the expression of this receptor on human peripheral blood cells. We
measured the binding of mAb 32 to monocytes and PMNs
isolated from healthy donors and from patients with group A
B3-hemolytic streptococcal (GABHS) pharyngitis. PMNs from
healthy donors (n = 12) had 700±600 (mean±SD) mAb 32
binding sites. Patients with pharyngitis and negative throat
culture for GABHS (n = 11) had 2,100±1,600 sites on their
PMNs. In contrast, the PMNs from patients with documented
GABHS pharyngitis (n = 12) had 11,600±7,500 mAb 32 binding sites on their surface. There was a similar change in the
expression of Fc'yRI on monocytes, with control monocytes
having a mean of 19,900±3,200 mAb 32 binding sites per cell
and the GABHS-positive monocytes having 47,500±21,400
sites. The GABHS-negative throat culture group had a slightly
elevated number of FcyRI with a mean of 28,200±8,400 sites.
10 patients with documented urinary tract infections and three
patients with uncomplicated pyelonephritis had no elevation in
FcyRI expression. These studies demonstrate that a localized
group A streptococcal infection can cause systemic activation
of the entire circulating pool of phagocytes, and suggest that a
similar level of activation is uncommon in localized gram-negative infections of the urinary tract. (J. Clin Invest. 1990.
86:1892-1896.) Key words: Fc receptors * interferon activation
* streptococcal infection
Introduction
Gamma interferon (IFN-'y),' a lymphokine secreted by activated T lymphocytes, has been shown to be a major mediator
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of resistance to infectious agents, including T. gondii (1), L.
monocytogenes (2), L. donovani (3), and R. conorii (4). IFN-'y
activates both murine and human mononuclear phagocytes,
increasing oxidative metabolism (5, 6), antimicrobial activity
(7, 8), and receptors for the Fc portion ofhuman immunoglobulin G (FcyR) (9, 10). Three FcyR (FcyRI, II, and III) have
been identified in association with human myeloid cells (reviewed by Unkeless et al., reference 1 1) and are recognized
respectively by monoclonal antibodies 32 (12), IV.3 (13), and
3G8 (14). FcyRI has high affinity for human IgG 1, is constitutively expressed on monocytes, and is induced to much
higher expression in response to IFN--y (9). Moreover, we recently used mAb 32 to show that while polymorphonuclear
neutrophils (PMNs) have < 3,000 FcyRI per cell, culture for
18 h with 40 U/ml of recombinant IFN-,y results in the expression of 8,000-20,000 Fc'yRI per PMN (15). Consistent
with this effect of IFN-y on monocytes and PMNs in vitro, it
has been demonstrated that parenteral administration of
rIFN-'y to patients causes increased expression of FcyRI on
circulating monocytes (16) and PMNs (Guyre P. M., and
M. B. Gamick, unpublished observations) and also increases
the capacity of monocytes to produce reactive oxygen intermediates (6).
Because streptococcal antigens are potent inducers of
IFN-'y production (17, 18), we postulated that FcyRI levels
would be elevated on monocytes and PMNs of patients who
have streptococcal infections. We therefore measured the
FcyRI levels on leukocytes from patients with group A (3 hemolytic streptococcal (GABHS) pharyngitis. In this report, we
show that monocytes and PMNs isolated from patients with
GABHS pharyngitis have increased expression of FcyRI, even
though IFN--y is undetectable in the plasma.

Methods
Study population. Patients presenting to the walk-in clinic at Dartmouth-Hitchcock Medical Center with sore throat and three or more
of the following criteria were eligible for the study: (a) anterior neck
adenopathy, (b) tonsillar exudates, (c) history of elevated temperature
during the present illness, and (d) absence of the new onset of cough.
These criteria were chosen to increase the probability of selecting patients with true streptococcal pharyngitis (19). Healthy volunteer
donors served as the control population. Patients presenting with sore
throat who met the criteria for inclusion, but who had a negative throat
culture for GABHS, were included in the study to serve as a second
control population. A third study population included afebrile patients
with a diagnosis of gram-negative urinary tract infection based on
symptomatic dysurea, leukocyturia, and 2 100,000 gram-negative
bacteria per milliliter of urine. Patients with the above symptoms plus
flank pain and fever were assigned the diagnosis of pyelonephritis.
Throat cultures were obtained from patients with pharyngitis by
posterior pharyngeal swab. Specimens were plated on trypticase
soy/5% sheep blood agar plates and incubated under anaerobic conditions. Plates were examined at 24 and 48 h for beta hemolysis. Colonies
of beta-hemolytic streptococci were further classified by latex agglutination grouping (Streptex, BBL Microbiology Systems, Baltimore MD)
Cell preparation. 20 ml of venous blood was collected into 1 0-ml
vacutainer tubes containing sodium heparin (Becton Dickinson,

Rutherford, NJ). Mononuclear cells were separated from PMN on
Ficoll/Hypaque according to Boyum (20). PMNs were separated from
RBC by dextran sedimentation (21). Nucleated cells were washed with
RPMI 1640 and contaminating RBC were removed by osmotic lysis;
osmolarity was restored with hypertonic PBS. Cells were washed again
with RPMI 1640 and resuspended in RPMI/Hepes/0.2% BSA. PMNs
and mononuclear cells were recombined in a 1:4 ratio because we
found this proportion to be optimal for analysis by flow cytometry.
Fc,yR assay. Fc-yR were examined by indirect immunofluoresence
staining using purified mAb specific to each of the three known FcyR
(15). These are mAb 32 (Fc-yRI; reference 12), mAb IV.3 (FcyRII;
reference 13) and mAb 3G8 (FcyRIII; reference 14). 6.25 X 105 cells in
20,u were added to flat bottomed 96-well plates on ice. Each well then
received 20 Id of human gamma globulin from a stock (12 mg/ml
Cohn Fraction V; Sigma Chemical Co., St. Louis, MO) to block binding of antibodies through their Fc region. 20 ,l of a 60 ,ug/ml stock of
mAb to the FcyR or a control mAb was then added to each ofthe wells.
Plates were rotated at 4°C for 1 h, cells were washed three times with
200 z1 PBS containing 0.2% BSA, and then incubated 1 h with a
saturating concentration of (Fab')2 FITC conjugated goat anti-mouse
IgG (Caltag Laboratories, South San Francisco, CA). After another 1-h
incubation, samples were washed 3X with PBS/BSA and resuspended
in PBS/BSA/1% paraformaldehyde. mAb binding was evaluated by
flow cytometry on an Ortho 50H flow cytometer using 300-mW, 488nm argon ion laser excitation, a 530-nm high pass filter, and a logarithmic amplifier. The relative number of mAb binding sites (reported as
2nd Ab sites/cell) was determined by comparing fluorescence of the
cells to a curve generated using standardized fluorescence beads (FHow
Cytometry Standards Corp., Research Triangle Park, NC) as described
previously (15). Statistical analysis was by Student's t test for unpaired
values.
IFN--y assays. Plasma was obtained from the same heparinized
tubes from which the leukocytes were isolated, made platelet-poor by
centrifugation at 450 g for 30 min, and frozen at -70°C for up to I mo
before assay. Five plasma samples were also tested within 2 h of isolation. Samples were tested using a commercially available radioimmunoassay (Centecor, Inc., Malvern, PA) which is specific for bioactive
IFN-,y, and by a bioassay which is based on increased expression of
Fc-yRI on U-937 cells that are cultured with the plasma and/or IFN--Y
(22). For the bioassay, 1 X 105 cells of the U-937 human promonocytic
cell line were cultured at 37°C, 5% C02 for 18-24 h in 96-well plates in
a total volume of 200 IdI in RPMI 1640 medium (Hazleton, Denver,
PA) supplemented with 20-80% plasma obtained from normal donors
or from GABHS patients. After incubation, these U-937 cells were
then analyzed by immunofluorescence flow cytometry for binding of
mAb 32.

Results
Streptococcal infection increases FcyRI. Fig. 1 A summarizes
the major finding of this study, that PMNs isolated on the day
of initial evaluation from eight of nine patients with GABHS
pharyngitis had significantly elevated levels of surface FcYRI.
PMNs from 12 healthy normal donors had 700±600
(mean±SD) mAb 32 binding sites. 11 patients with pharyngitis
and negative throat culture for GABHS had a mean of
2,100±1,600 sites on their PMNs, a value significantly higher
than for controls (P < 0.05). In contrast, PMNs from nine
patients with documented GABHS pharyngitis had
11,600±7,500 mAb 32 binding sites on their surface. This was
significantly higher than both the healthy donor group (P
< 0.0005) and the GABHS-negative throat culture group (P
< 0.0005). The GABHS-negative group included three patients (Nos. 2, 4, and 6, of Fig. 1, middle) who had cultures
containing many f3-hemolytic streptococci that were non
group A. None of the PMNs from the 12 healthy donors expressed > 2,1 00 sites and none of the GABHS-negative culture
group expressed > 5,000 sites. However, eight of nine patients
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Figure 1. FcyRI levels are increased on PMNs (A) and monocytes
(B) of patients with group A /-hemolytic streptococcal (GABHS)
pharyngitis. Values are relative mAb 32 binding sites per cell calculated as described (I15). Each bar is the value for a single donor.

with positive GABHS cultures had more than 6,000 sites per
PMN. One patient (No. 7, Fig. 1, right) with a laboratory
finding of "moderate" GABHS had control values for mAb 32
binding on both her PMNs and monocytes.
There was a similiar change in the expression of FcyRI on
monocytes (Fig. 1 B), with control monocytes having
19,900+3,200 mAb 32 binding sites per cell and the positive
GABHS monocytes having 47,500+21,400 mAb 32 binding
sites (P < 0.0005). The negative culture group had slightly
elevated FcyRI with a mean of 28,200±8,400 sites. This was
significantly different from both the normal controls (P
< 0.05) and from the positive GABHS group (P < 0.005).
When cells from each GABHS positive donor were compared,
there was a close correlation between elevated FcyRI levels on
PMNs (Fig. 1 A, right) and on monocytes (Fig. 1 B, right).
During this study, one donor in the control group developed
GABHS pharyngitis 6 mo after she was initially studied. For
this donor, the number of mAb 32.2 binding sites per PMN
increased from 1,900 before infection to 13,800 sites per cell
during infection. FcyRI per monocyte increased from 22,800
to 53,400 sites per cell.
Flow cytometric analysis enabled us to determine whether
the increased expression of Fc"yRI appeared on all cells or only
on a subpopulation. Fig. 2 shows idealized histograms of the
distribution that was found for all GABHS patients. In every
case, the entire population of monocytes and PMNs displayed
increased receptor expression.
To further determine the relationship between the disease
process and FcyRI expression, we examined three additional
patients for FcyRI expression after they were identified by the
laboratory as having a positive throat culture for GABHS.
When these people were examined within 24 h after the specimen was obtained, they had elevated mAb32 binding sites on
both monocytes and PMNs (Fig. 3). Fig. 3 includes the values
Fc-yRI Increases with Infection
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Figure 2. Immunofluorescence profiles for flow cytometric analysis
of mAb 32 binding to granulocytes (A) and monocytes (B). Cells
were isolated, stained, and analyzed as described in Methods.

for one donor (C.G.) who was followed sequentially for 3 d.
This donor had markedly elevated FcyRI on both monocytes
and PMN 24 h after the throat culture was obtained, but
FcyRI values dropped to normal after two additional days.
Streptococcal infection does not alter FcyRII or FcyRIII.
Two additional IgG Fc receptors, FcyRII and FcyRIII, are
present on human myeloid cells (1 1). Although these FcyR are
not markedly affected by IFN-'y in cell culture, we were interested to determine whether their expression was altered by
streptococcal infection. We therefore used mAbs IV.3 and
3G8 to measure Fc'yRII and FcyRIII, respectively. Fig. 4
shows that the levels of binding of these mAbs were equivalent
for all three groups. Thus, in contrast to FcyRI, the expression
of FcyRII and FcyRIII was unaffected by GABHS infection.
500()0-
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Figure 4. FcyRII and FcyRIII levels are unchanged on leukocytes of
GABHS pharyngitis patients. Values are mean±SD mAb IV.3
(Fc-yRII) and mAb 3G8 (Fc-yRIII) sites per cell for the healthy control group (n = 12), the culture negative group (n = 11), and the
GABHS pharyngitis positive group (n = 9).

Gram negative urinary tract infection does not alter FcyRI
expression. 10 patients with documented urinary tract infections were found to not have increased binding of mAb 32 to
monocytes or PMN (Table I). Three patients with apparently
uncomplicated pyelonephritis had a mean of 33,500 binding
sites on their monocytes and 3,400 sites on their PMN, levels
similar to pharyngitis patients who were GABHS negative.
Two additional pyelonephritis patients had elevated FcyRI on
their PMNs. These patients, in addition to pyelonephritis, also
had either E. coli septicemia or pneumonia of unknown etiology (Table I).
IFN-,y is undetectable in patient's plasma. IFN-'y is a potent inducer of Fc-yRI expression by both monocytes and
PMNs (9, 10, 15) and its production is induced by streptococcal antigens (17, 18). We therefore examined plasma samples,
obtained at the same time that elevated numbers of FcyRI
were detected on leukocytes, for the presence of IFN--y. Seven
plasma samples were obtained and frozen at -70°C, then
tested using an IFN-y-specific RIA (Centocor, Inc., Malvern,
PA). All samples had undetectable IFN-'y (< 1 U/ml).
We next obtained blood from three donors as soon as possible after their throat cultures were found to contain GABHS,
examined the cells for FchyRI expression, and tested the plasma
within 2 h of isolation for IFN-,y. This test for IFN--y included
both the RIA and a bioassay (22) which detects increased expression of FcyRI on the U-937 cell line. Fig. 5 shows the
result for plasma samples obtained from donors K.B. and
A.L.; leukocyte Fc'yRI levels for the same blood samples are
shown to be elevated in Fig. 3. Neither plasma from the normal donor (CON) nor from the GABHS patients (K.B. and
A.L.) caused a significant increase in mAb 32 binding to
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Table I. MAb 32 Binding in Gram-negative Infections
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Figure 3. Fc-yRI levels on monocytes and PMNs of three donors examined after the throat culture was shown to contain GABHS.
Times shown are hours after the initial clinical evaluation that subsequent blood samples were obtained.
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Diagnosis

Monocytes

PMN

Urinary tract infection (n = 10)
Pyelonephritis (n = 3)
Pyelonephritis + E. coli septicemia
(n = 1)
Pyelonephritis + pneumonia
(n = 1)

18000±5100
33500±3000

1580±1200
3400±2500

4300

6200

31900

10660

* Relative mAb 32 sites per cell determined by immunofluorescence
plus flow cytometry as described in reference 15.

TREATMIENT
A.L. + IFN
A.L. + B3
A.L.
K.B. + IFN
K.B. + B3
K.B.
CON + IFN + B3
CON + IFN
CON + B3

OCN
0

5000 10000 15000 20000
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25000

Figure 5. Bioassay of plasma for IFN-'y. Plasma obtained from two
patients (A.L. and K.B.) or from a control donor (CON) was tested
for its ability to induce increased expression of FcyRI on U937 cells
as described in Methods. Values are relative mAb 32 binding sites
per U937 cell after culture with plasma (CON, K.B., or A.L.),
plasma plus mAb B3 (which neutralizes IFN-'y), or plasma plus 1
U/ml IFN-y.

U-937 cells that were cultured with 40% plasma for 18 h.
However, each plasma sample, when supplemented with 1
U/ml rIFN-'y, caused a 40% increase in FcyRI expression,
which was blocked by the IFN-,y neutralizing monoclonal antibody B3 (23). This experiment demonstrates that the bioassay detects as little as 0.4 U/ml IFN--y, and that the plasma
from GABHS patients who have elevated FcyRI levels on their
leukocytes contains < 1 U/ml IFN-,y. Additional assay points
(not shown) included 60 and 80% plasma, and gave similar
results, leading us to conclude that the plasma samples tested
contained < 0.5 U/ml IFN-'y.

Discussion
Because Fc receptors mediate the ingestion of opsonized bacteria, a mechanism to increase Fc receptor expression during
infection would seem to be physiologically important. In previous reports, we and others showed that IFN-y causes a dramatic increase in expression of FcoyRI on monocytes, the
monocyte like cell line U-937, and PMNs, both in vitro and in
vivo (9, 10, 15, 16). Because streptococcal antigens are potent
inducers of IFN-'y (18, 19), we postulated that IFN-'y would be
produced endogenously in vivo in patients with streptococcal
infections. With the studies presented in this paper, we have in
fact demonstrated that Fc-yRI expression is induced on PMNs
and augmented on monocytes isolated from patients with
GABHS pharyngitis. However, we were unable to detect
IFN--y in the plasma of these patients, even when their FcoyRI
levels were very high, and the plasma was tested immediately
upon isolation. In other experiments (not shown), we determined that the activity of rIFN--y was not reduced by adding it
to GABHS plasma or by storage at -70°C. Because both our
bioassay and the RIA had sensitivities in the range of 1 U/ml
IFN-y, we conclude that circulating levels of IFN-y are below
this level even in patients, such as K.B. (Figs. 3 and 5), who
were febrile and had greatly elevated expression of FcyRI
when the blood sample was obtained.
The absence of detectable IFN-,y in the circulation suggests: (a) that elevated FcyRI may be mediated by locally high
concentrations of IFN-y, (b) that the short circulating half-life
of IFN--y may result in undetectable levels even though levels
were initially high; or (c) that other cytokines or hormones
may contribute to increased FcyRI in addition to (or instead
of) IFN-y. The first possibility seems unlikely since the entire
population of monocytes and PMNs, rather than a subpopu-

lation, had elevated FcyRI (Fig. 2). Thus, streptococcal infection results in systemic activation of FcyRI expression in all
circulating monocytes and PMNs. The second possibility is
plausible since the serum half-life of rIFN-y has been estimated to be between 0.5 and 3 h (24-26). Moreover, Chatenoud et al. (27) reported a rapid induction and rapid decline in
serum IFN-'y levels following clinical administration of mAb
OKT3 for prevention of acute allograft rejection. Thus, IFN-y
levels could transiently be as high as 1,000 U/ml and then fall
to undetectable levels 24 h later. To further test the plausibility
of this hypothesis, we exposed two groups of PMN to 50 U/ml
IFN-y for 3 h, washed out the IFN-'y from one group, and then
cultured the cells for an additional 18 h. The two groups had
similar increases in FcyRI, indicating that transient exposure
to IFN-y is sufficient to induce increased FcyRI expression 18
h later on human PMNs. It will be interesting to determine
whether OKT3 therapy stimulates a similar increase in FcyRI
expression.
To test the possibility that other cytokines might influence
the expression of FcyRI, we cultured PMNs with recombinant
IFN-a, IFN-j, interleukin 2, interleukin 3, tumor necrosis
factor, granulocyte-colony stimulating factor (G-CSF), and
granulocyte/macrophage-colony stimulating factor, both
alone and in combination with 50 U/ml IFN-,y. IFN--y caused
a 10- to 20-fold increase in FcyRI as previously reported (15),
and G-CSF caused a two- to three-fold increase that was additive with that of IFN-y (manuscript in preparation). None of
the other cytokines enhanced FcyRI expression. Further study
will be required to determine whether a combination of immune cytokines and/or other hormones can increase FcyRI
expression sufficiently to account for the effects we have observed in GABHS patients.
Patients who met the criteria for inclusion in this study but
had negative throat cultures most likely represented cases of
viral infection. It is interesting that FcyRI expression was increased to a much lesser extent on PMNs and monocytes in
these patients. PMNs from all donors in the control and
GABHS culture-negative groups had < 5,000 mAb 32 sites per
cell, while PMNs from 11 of 12 GABHS culture-positive
donors had > 6,000 sites per cell. The one sample that did not
show a rise in FcyRI may have been a false positive case in
which the patient was colonized but not infected with GABHS.
It is also possible that this patient was indeed infected with
GABHS, but did not respond to infection by increased FcyRI
expression. It will be interesting to determine whether there is
a relationship between protracted streptococcal infections and
a failure to exhibit increased FcyRI expression. Further study
will be required to determine whether a combination of immune cytokines and/or other hormones can increase FcyRI
expression sufficiently to account for the effect we have observed in GABHS patients.
Although streptococcal pharyngitis represents a relatively
minor bacterial infection, we have demonstrated that this degree of infection is able to systematically activate the immune
system, as evidenced by increased FcyRI expression on peripheral blood myeloid cells. It seems likely, therefore, that
patients with systemic infectious illness will also have elevated
levels of FcyRI. Consistent with this possibility, PMNs isolated from patients seriously ill with bacterial and fungal sepsis
have been shown to be activated, as demonstrated by an increased capacity for maximal superoxide production (28).
FcyR expression was not evaluated in these patients. However, Simms et al. (29) used radiolabeled mAb 32 to demonstrate that two patients with acute bacterial infections had inFcyRI Increases with Infection
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creased FcyRI expression on their PMNs. The same authors
found FcyRII and Fc'yRIII expression to be similar on patient
and control PMNs. It can thus be concluded from our study
and that of Simms et al. that FcyRI is selectively increased in
at least some bacterial infections. Moreover, our data show
that gram-negative urinary tract infections do not activate the
mechanisms leading to increased expression of FcyRI. Also,
although our sample size is small, it is apparent that E. coli
pyelonephritis causes a lower level of activation than does
GABHS infection.
In summary, we find increased FcyRI expression on the
entire circulating pool of both PMNs and monocytes isolated
from patients with GABHS pharyngitis. This increase might
result from a transiently high level of production of IFN-y and
G-CSF, but probably reflects the interactive effects of several
as yet to be identified hormones and cytokines. Further studies
will be required to determine the types of infectious illnesses
that are associated with increased expression of Fc-yRI.

Acknowledgments
We appreciate the assistance of Rosemary Bruce, R.N., Richard Delaney, PA-C, and Nick Jacobs, Ph.D. in obtaining specimens. We
thank Milton Brown, Veronica Guyre, and Gary Ward for their help
with flow cytometric analysis, and Sharon Fanger for her unique editorial assistance. MAbs IV.3, 3G8, and B3 were kindly provided by Clark
Anderson, Jay Unkeless, and Junming Le, respectively. Interferons
were generous gifts of Genentech, Inc. and Hoffman LaRoche, Inc.
Other cytokines were kindly provided by Immunex, Inc.
This work was supported by National Institutes of Health grants
DK 33100, CA 17323, Al 19053, and CA 44794. The cytofluorograph
was the generous gift of the Fannie Rippel Foundation, and is partially
supported by the core grant of the Norris Cotton Cancer Center
(CA23 108).

References
1. Suzuki, Y., M. A. Orellana, R. D. Schreiber, and J. S. Remington. 1988. Interferon--y: the major mediator ofresistance against Toxo-

plasma gondii. Science (Wash. DC). 240:516-518.
2. Buchmeier, N. A., and R. D. Schreiber. 1985. Requirement of
endogenous interferon-y production for the resolution of Listeria
monocytogenes infection. Proc. Natl. Acad. Sci. USA. 82:7404-7408.
3. Murray, H. W., B. Y. Rubin, and C. D. Rothermel. 1983. Killing
of intracellular Leishmania donovani by human mononuclear phagocytes. Evidence that interferon-y is the activating lymphokine. J. Clin.
Invest. 72:1506-1510.
4. Li, H., T. R. Jerrells, G. L. Spitalny, and D. H. Walker. 1987.
Gamma interferon as a crucial host defense against Rickettsia conorii
in vivo. Infect. Immun. 55:1252-1255.
5. Murray, H. W., G. L. Spitalny, and C. F. Nathan. 1985. Activation of mouse peritoneal macrophages in vitro and in vivo by inter-

feron-y. J. Immunol. 134:1619-1622.
6. Nathan, C. F., C. R. Horowitz, J. de la Horpe, S. Vadhan-Raj,
H. F. Sherwin, and S. E. Krown. 1985. Administration of recombinant
interferon--y to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc. Natl. Acad. Sci. USA. 82:8686-8690.
7. Varesio, L., E. Blasi, G. B. Thurman, J. E. Talmadge, R. H.
Wiltrout, and R. B. Herberman. 1984. Potent activation of mouse
macrophages by recombinant IFN-,y. Cancer Res. 44:4465-4469.
8. Nathan, C. F., T. J. Prendergast, M. E. Wiebe, E. R. Stanley, E.
Platzer, H. G. Remold, K. Welte, B. Y. Rubin, and H. W. Murray.
1984. Activation of human macrophages: comparison of other cyto-

kines with interferon-y. J. Exp. Med. 160:600-605.
9. Guyre, P. M., P. M. Morganelli, and R. Miller. 1983. Recombinant immune interferon increases immunoglobulin G Fc receptors on
cultured mononuclear phagocytes. J. Clin. Invest. 72:393-397.
1896

P. M. Guyre, A. S.

Campbell, W. D. Kniffin, and M. W. Fanger

10. Perussia, B., E. T. Dayton, V. F. Lazarus, and G. Trinchieri.
1983. Immune interferon induces the receptor for monomeric IgG 1 on
human monocytic and myeloid cells. J. Exp. Med. 158:1092-1113.
1 1. Unkeless, J. C. 1989. Function and heterogeneity of human Fc
receptors for immunoglobulin G. J. Clin. Invest. 83:355-361.
12. Anderson, C. L., P. M. Guyre, J. C. Whitin, D. H. Ryan, R. J.
Looney, and M. W. Fanger. 1986. Monoclonal antibodies to the Fc
receptors for IgG on human mononuclear phagocytes: antibody characterization and induction of superoxide production in a monocyte
cell line. J. Biol. Chem. 261:12856-12864.
13. Looney, R. J., G. N. Abraham, and C. L. Anderson. 1986.
Human monocytes and U937 cells bear two distinct Fc receptors for
IgG. J. Immunol. 136:1641-1647.
14. Fleit, H. B., S. D. Wright, and J. W. Unkeless. 1982. Human
neutrophil Fc-y receptor distribution and structure. Proc. Natl. Acad.
Sci. USA. 79:3275-3279.
15. Petroni, K. C., L. Shen, and P. M. Guyre. 1988. Modulation of
human polymorphonuclear leukocyte IgG Fc receptors and Fc receptor-mediated functions by IFN-y and glucocorticoids. J. Immunol.
140:3467-3472.
16. Maluish, A. E., W. J. Urba, D. L. Longo, W. R. Overton, D.
Coggin, E. R. Crisp, R. Williams, S. A. Sherwin, K. Gordon, and R. G.
Steis. 1988. The determination of an immunologically active dose of
interferon gamma in patients with melanoma. J. Clin. Oncol. 6:434445.
17. Matsubara, S., F. Suzuki, and N. Ishida. 1979. Induction of
immune interferon in mice treated with a bacterial immunopotentiator, OK 432. Cancer Immunol. Immunother. 6:41-46.
18. Kimura, S., T. Inoue, T. Yamashita, Y. Midorikawa, S. Arai,
and F. Sendo. 1987. Production of factor(s) that render polymorphonuclear leukocytes cytotoxic from spleen cells stimulated with streptococcal preparation, OK-432. Cancer Res. 47:6204-6209.
19. Centor, R. M., J. M. Witherspoon, H. P. Dalton, C. E. Brody,
and K. Link. 1981. The diagnosis of strep throat in the emergency
room. Med. Decis. Making. 1:239-246.
20. Boyum, A. 1968. Isolation of mononuclear cells and granulocytes from human blood. J. Lab. Clin. Invest. 21(Suppl. 97):77.
21. Graziano, R. F., and M. W. Fanger. 1987. FcyRI and Fc-yRII
on monocytes and granulocytes are cytotoxic trigger molecules for
tumor cells. J. Immunol. 139:3536-3541.
22. Guyre, P. M., P. M. Morganelli, F. Fillian, R. Miller, and J. E.
Bodwell. 1984. Virus-free bioassay of human immune interferon by
flow cytometric analysis of Fc receptor modulation. Fed. Proc.
43:1830.
23. Le, J., and J. Vilcek. 1984. Lymphokine-mediated activation of
human monocytes: neutralization by monoclonal antibody to interferon-y. Cell Immunol. 85:278-283.
24. van der Burg, M., M. Edelstein, L. Gerlis, C.-M. Liang, M.
Hirschi, and A. Dawson. 1985. Recombinant interferon-y (immuneron): results of a phase I trial in patients with cancer. J. Biol. Resp.
Modifiers. 4:264-272.
25. Foon, K. A., S. A. Sherwin, P. G. Abrams, H. C. Stevenson, P.
Holmes, A. E. Maluish, R. K. Oldham, and R. B. Herberman. 1985. A
phase I trial of recombinant gamma interferon in patients with cancer.
Cancer Immunol. Immunother. 20:193-197.
26. Vadhan-Raj, S., A. Al-Katib, R. Bhalla, L. Pelus, C. F. Nathan,
S. A. Sherwin, H. F. Oettgen, and S. E. Krown. 1986. Phase I trial of
recombinant interferon gamma in cancer patients. J. Clin. Oncol.
4:137-146.
27. Chatenoud, L., C. Ferran, C. Legendre, P. Franchimont, A.
Reuter, H. Kreis, and J.-F. Bach. 1988. Clinical use of OKT3: the role
of cytokine release and xenosensitization. J. Autoimmunity. 1:631640.
28. Bass, D. A., P. Olbrantz, P. Szejda, M. C. Seeds, and C. E.
McCall. 1986. Subpopulations of neutrophils with oxidative product
formation in blood of patients with infection. J. Immunol. 136:860866.
29. Simms, H. H., M. M. Frank, T. C. Quinn, S. Holland, and T.
Gaither. 1989. Studies on phagocytosis in patients with acute bacterial
infections. J. Clin. Invest. 83:252-260.

